Cargando…
COVID-19 in Recent Lung Transplant Recipients: Clinical Outcomes and Management Strategies
BACKGROUND: COVID-19 causes a wide range of symptoms, with particularly high risk of severe respiratory failure and death in patients with predisposing risk factors such as advanced age or obesity. Recipients of solid organ transplants, and in particular lung transplantation, are more susceptible to...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743506/ https://www.ncbi.nlm.nih.gov/pubmed/35120764 http://dx.doi.org/10.1016/j.transproceed.2021.12.014 |
_version_ | 1784629916532211712 |
---|---|
author | Zimmermann, Julia Glueck, Olaf M. Fertmann, Jan M. Sienel, Wulf G. Yavuz, Gökce Damirov, Fuad Kovács, Julia R. Tufman, Amanda Irlbeck, Michael Kneidinger, Nikolaus Michel, Sebastian Kauke, Teresa Hatz, Rudolf A. Schneider, Christian P. |
author_facet | Zimmermann, Julia Glueck, Olaf M. Fertmann, Jan M. Sienel, Wulf G. Yavuz, Gökce Damirov, Fuad Kovács, Julia R. Tufman, Amanda Irlbeck, Michael Kneidinger, Nikolaus Michel, Sebastian Kauke, Teresa Hatz, Rudolf A. Schneider, Christian P. |
author_sort | Zimmermann, Julia |
collection | PubMed |
description | BACKGROUND: COVID-19 causes a wide range of symptoms, with particularly high risk of severe respiratory failure and death in patients with predisposing risk factors such as advanced age or obesity. Recipients of solid organ transplants, and in particular lung transplantation, are more susceptible to viral infection owing to immune suppressive medication. As little is known about the SARS-CoV-2 infection in these patients, this study was undertaken to describe outcomes and potential management strategies in early COVID-19 infection early after lung transplantation. METHODS: We describe the incidence and outcome of COVID-19 in a cohort of recent lung transplant recipients in Munich. Six of 186 patients who underwent lung transplantation in the period between March 2019 and March 2021 developed COVID-19 within the first year after transplantation. We documented the clinical course and laboratory changes for all patients showing differences in the severity of the infection with COVID-19 and their outcomes. RESULTS: Three of 6 SARS-CoV-2 infections were hospital-acquired and the patients were still in inpatient treatment after lung transplantation. All patients suffered from symptoms. One patient did not receive antiviral therapy. Remdesivir was prescribed in 4 patients and the remaining patient received remdesivir, bamlanivimab and convalescent plasma. CONCLUSIONS: COVID-19 does not appear to cause milder disease in lung transplant recipients compared with the general population. Immunosuppression is potentially responsible for the delayed formation of antibodies and their premature loss. Several comorbidities and a general poor preoperative condition showed an extended hospital stay. |
format | Online Article Text |
id | pubmed-8743506 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87435062022-01-10 COVID-19 in Recent Lung Transplant Recipients: Clinical Outcomes and Management Strategies Zimmermann, Julia Glueck, Olaf M. Fertmann, Jan M. Sienel, Wulf G. Yavuz, Gökce Damirov, Fuad Kovács, Julia R. Tufman, Amanda Irlbeck, Michael Kneidinger, Nikolaus Michel, Sebastian Kauke, Teresa Hatz, Rudolf A. Schneider, Christian P. Transplant Proc Article BACKGROUND: COVID-19 causes a wide range of symptoms, with particularly high risk of severe respiratory failure and death in patients with predisposing risk factors such as advanced age or obesity. Recipients of solid organ transplants, and in particular lung transplantation, are more susceptible to viral infection owing to immune suppressive medication. As little is known about the SARS-CoV-2 infection in these patients, this study was undertaken to describe outcomes and potential management strategies in early COVID-19 infection early after lung transplantation. METHODS: We describe the incidence and outcome of COVID-19 in a cohort of recent lung transplant recipients in Munich. Six of 186 patients who underwent lung transplantation in the period between March 2019 and March 2021 developed COVID-19 within the first year after transplantation. We documented the clinical course and laboratory changes for all patients showing differences in the severity of the infection with COVID-19 and their outcomes. RESULTS: Three of 6 SARS-CoV-2 infections were hospital-acquired and the patients were still in inpatient treatment after lung transplantation. All patients suffered from symptoms. One patient did not receive antiviral therapy. Remdesivir was prescribed in 4 patients and the remaining patient received remdesivir, bamlanivimab and convalescent plasma. CONCLUSIONS: COVID-19 does not appear to cause milder disease in lung transplant recipients compared with the general population. Immunosuppression is potentially responsible for the delayed formation of antibodies and their premature loss. Several comorbidities and a general poor preoperative condition showed an extended hospital stay. Elsevier Inc. 2022 2022-01-10 /pmc/articles/PMC8743506/ /pubmed/35120764 http://dx.doi.org/10.1016/j.transproceed.2021.12.014 Text en © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Zimmermann, Julia Glueck, Olaf M. Fertmann, Jan M. Sienel, Wulf G. Yavuz, Gökce Damirov, Fuad Kovács, Julia R. Tufman, Amanda Irlbeck, Michael Kneidinger, Nikolaus Michel, Sebastian Kauke, Teresa Hatz, Rudolf A. Schneider, Christian P. COVID-19 in Recent Lung Transplant Recipients: Clinical Outcomes and Management Strategies |
title | COVID-19 in Recent Lung Transplant Recipients: Clinical Outcomes and Management Strategies |
title_full | COVID-19 in Recent Lung Transplant Recipients: Clinical Outcomes and Management Strategies |
title_fullStr | COVID-19 in Recent Lung Transplant Recipients: Clinical Outcomes and Management Strategies |
title_full_unstemmed | COVID-19 in Recent Lung Transplant Recipients: Clinical Outcomes and Management Strategies |
title_short | COVID-19 in Recent Lung Transplant Recipients: Clinical Outcomes and Management Strategies |
title_sort | covid-19 in recent lung transplant recipients: clinical outcomes and management strategies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743506/ https://www.ncbi.nlm.nih.gov/pubmed/35120764 http://dx.doi.org/10.1016/j.transproceed.2021.12.014 |
work_keys_str_mv | AT zimmermannjulia covid19inrecentlungtransplantrecipientsclinicaloutcomesandmanagementstrategies AT glueckolafm covid19inrecentlungtransplantrecipientsclinicaloutcomesandmanagementstrategies AT fertmannjanm covid19inrecentlungtransplantrecipientsclinicaloutcomesandmanagementstrategies AT sienelwulfg covid19inrecentlungtransplantrecipientsclinicaloutcomesandmanagementstrategies AT yavuzgokce covid19inrecentlungtransplantrecipientsclinicaloutcomesandmanagementstrategies AT damirovfuad covid19inrecentlungtransplantrecipientsclinicaloutcomesandmanagementstrategies AT kovacsjuliar covid19inrecentlungtransplantrecipientsclinicaloutcomesandmanagementstrategies AT tufmanamanda covid19inrecentlungtransplantrecipientsclinicaloutcomesandmanagementstrategies AT irlbeckmichael covid19inrecentlungtransplantrecipientsclinicaloutcomesandmanagementstrategies AT kneidingernikolaus covid19inrecentlungtransplantrecipientsclinicaloutcomesandmanagementstrategies AT michelsebastian covid19inrecentlungtransplantrecipientsclinicaloutcomesandmanagementstrategies AT kauketeresa covid19inrecentlungtransplantrecipientsclinicaloutcomesandmanagementstrategies AT hatzrudolfa covid19inrecentlungtransplantrecipientsclinicaloutcomesandmanagementstrategies AT schneiderchristianp covid19inrecentlungtransplantrecipientsclinicaloutcomesandmanagementstrategies |